Phase II study of combination chemotherapy of gemcitabine, TS-1 and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Not Applicable
- Conditions
- nresectable advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000008413
- Lead Sponsor
- Jikei University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pulmonary fibrosis or interstitial pneumonia detectable on chest X-ray 2)Active infection 3)Uncontrollable heart disease and myocardial infarction within 6 months 4)Uncontrollable DM 5)Pregnant or lactation women, or women with known or suspected pregnancy 6)History of severe drug allergy 7)Active synchronous or metachronous malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival, PFS, Disease control rate, one-year survival rate
- Secondary Outcome Measures
Name Time Method